Embryonic Stem Cell Experimentation


Embryonic Stem Cell Experimentation: Bush’s “Broken Promise”

For Immediate Release

August 10, 2001

Contact Scott Weinberg
(540) 622-5240

Mosher: “Even limited funding for embryonic stem cell experimentation may lead to unlimited disregard for human life”

WASHINGTON, DC — “In approving so-called limited funding for destructive experimentation on embryonic stem cells, the President has opened the door to the limitless destruction of human life,” said Steven Mosher, president of Population Research Institute.

Mosher said he was “gravely concerned and extremely disappointed” by the President’s “broken promise” – Bush’s decision to approve federal funding for experimentation on an estimated 60 stem cell lines, developed from stem cells harvested from human embryos, killing them in the process.

Mosher condemned the decision, saying that “Never before have federal funds been used for such research — research which to date has demonstrated no therapeutic benefits. Pandora’s box is now open, and federal money will create a market for the development of more stem cell lines, overseas if not here at home, with the resulting destruction of human embryos. Already the cry for the destruction of almost 200,000 frozen embryos is being raised by those who would profit from their demise.”

Mosher’s statements came amidst reports of irregularities in campaign contributions from the biotech lobby to Secretary of Health and Human Services, Tommy Thompson, and lawmakers supportive of human embryonic stem cell research.

“The potential for profits by biotech corporations, the State of Wisconsin and its state-funded university, are a matter of public record,” Mosher pointed out. “But to pursue scientific advance without concern for the dignity of the human person will dehumanize us all.”

To interview Steven Mosher, E-mail [email protected]

Never miss an update!

Get our Weekly Briefing! We send out a well-researched, in-depth article on a variety of topics once a week, to large and growing English-speaking and Spanish-speaking audiences.

Subscribe to our Weekly Briefing!

Receive expert analysis every Tuesday morning.
This field is for validation purposes and should be left unchanged.